Keith Bourgeois, MD
Retina Specialist · Houston, TXNPI 1457312183
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,625 of the $7,147 with a category attached, or 78.7%. AbbVie accounts for 92.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $6,697 and has fallen 99.5% since, to $36 in 2025.
Across 27 payments — averaging $264.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Genentech USA, Inc.$187
- Novartis$173
- Regeneron Healthcare Solutions, Inc.$117
- Alimera Sciences, Inc.$71
- Dutch Ophthalmic, USA$18
What the payments were for
- Consulting fees$5,62579%
- Travel & lodging$5588%
- Food & beverage$96313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $6,581 |
| Genentech USA, Inc. | 4 | $187 |
| Novartis | 2 | $173 |
| Regeneron Healthcare Solutions, Inc. | 4 | $117 |
| Alimera Sciences, Inc. | 3 | $71 |
| Dutch Ophthalmic, USA | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,147 in reported general payments places this provider in the 70th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 12 | $3,976 |
| Prednisolone Acetate | 107 | $3,245 |
| Timolol Maleate | 77 | $2,305 |
| Brimonidine Tartrate | 25 | $1,194 |
| Difluprednate | 14 | $1,133 |
| Latanoprost | 57 | $570 |
| Diclofenac Sodium | 58 | $493 |
| Gentamicin Sulfate | 67 | $469 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Houston
- Garvin DavisHouston$38K
- Ella LeungHouston$12K
- Lindsey HarrisHouston$10K
- Petros CarvounisHouston$8K
- Richard FishHouston$5K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
- Sapa PhamHouston$4K
- Jie GaoHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.